Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium : DA VINCI observational study
BACKGROUND: Cardiovascular disease (CVD) is one of the leading causes of death in Belgium. Current strategies for the prevention and management of CVD focus on reducing low-density lipoprotein cholesterol (LDL-C) levels. This analysis assessed whether LDL-C goals, recommended by the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines, were being achieved in a Belgian study population.
METHODS: The cross-sectional, observational, DA VINCI study enrolled patients prescribed lipid-lowering therapy (LLT) between 21 June 2017 and 20 November 2018. Data for patients from Belgium were extracted for this country-specific analysis. Primary endpoint was the proportion of patients who achieved 2016 ESC/EAS risk-based LDL-C goals; attainment of 2019 risk-based LDL-C goals was evaluated post hoc.
RESULTS: Of 497 enrolled patients, 41% were female and mean age was 68 years. Among subjects with an LDL-C measurement on stabilised LLT, moderate-intensity statin monotherapy was the most prescribed LLT regimen (59%). Overall, 63% of patients achieved their risk-based LDL-C goals according to the 2016 ESC/EAS guidelines. Among patients with established ASCVD, risk-based LDL-C goal attainment was higher in patients with peripheral arterial disease (53%) than patients with coronary (37%) and cerebrovascular disease (42%). According to the updated 2019 ESC/EAS guidelines, less than half (41%) of patients achieved their risk-based LDL-C goal. The proportion of primary and secondary prevention patients who achieved 2019 risk-based LDL-C goals was 59% and 18%, respectively.
CONCLUSION: These findings reveal a large gap between the LDL-C goals advocated by the ESC/EAS and the levels achieved in routine clinical practice in Belgium.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Acta cardiologica - 79(2024), 1 vom: 14. Feb., Seite 20-29 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van de Borne, Philippe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular disease |
|---|
| Anmerkungen: |
Date Completed 08.03.2024 Date Revised 08.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/00015385.2022.2030568 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33971428X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33971428X | ||
| 003 | DE-627 | ||
| 005 | 20240308231904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/00015385.2022.2030568 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1320.xml |
| 035 | |a (DE-627)NLM33971428X | ||
| 035 | |a (NLM)35442151 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van de Borne, Philippe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium |b DA VINCI observational study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.03.2024 | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Cardiovascular disease (CVD) is one of the leading causes of death in Belgium. Current strategies for the prevention and management of CVD focus on reducing low-density lipoprotein cholesterol (LDL-C) levels. This analysis assessed whether LDL-C goals, recommended by the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines, were being achieved in a Belgian study population | ||
| 520 | |a METHODS: The cross-sectional, observational, DA VINCI study enrolled patients prescribed lipid-lowering therapy (LLT) between 21 June 2017 and 20 November 2018. Data for patients from Belgium were extracted for this country-specific analysis. Primary endpoint was the proportion of patients who achieved 2016 ESC/EAS risk-based LDL-C goals; attainment of 2019 risk-based LDL-C goals was evaluated post hoc | ||
| 520 | |a RESULTS: Of 497 enrolled patients, 41% were female and mean age was 68 years. Among subjects with an LDL-C measurement on stabilised LLT, moderate-intensity statin monotherapy was the most prescribed LLT regimen (59%). Overall, 63% of patients achieved their risk-based LDL-C goals according to the 2016 ESC/EAS guidelines. Among patients with established ASCVD, risk-based LDL-C goal attainment was higher in patients with peripheral arterial disease (53%) than patients with coronary (37%) and cerebrovascular disease (42%). According to the updated 2019 ESC/EAS guidelines, less than half (41%) of patients achieved their risk-based LDL-C goal. The proportion of primary and secondary prevention patients who achieved 2019 risk-based LDL-C goals was 59% and 18%, respectively | ||
| 520 | |a CONCLUSION: These findings reveal a large gap between the LDL-C goals advocated by the ESC/EAS and the levels achieved in routine clinical practice in Belgium | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a cholesterol | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a statins | |
| 650 | 7 | |a Cholesterol, LDL |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Peeters, André |e verfasserin |4 aut | |
| 700 | 1 | |a Janssens, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Attilio |e verfasserin |4 aut | |
| 700 | 1 | |a Lemmens, Robin |e verfasserin |4 aut | |
| 700 | 1 | |a Verhaegen, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a De Meulemeester, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Balthazar, Yohan |e verfasserin |4 aut | |
| 700 | 1 | |a Heijmans, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Calozet, Yvan |e verfasserin |4 aut | |
| 700 | 1 | |a Paquot, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Carlier, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Hemelsoet, Dimitri |e verfasserin |4 aut | |
| 700 | 1 | |a Bray, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Kausik K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta cardiologica |d 1946 |g 79(2024), 1 vom: 14. Feb., Seite 20-29 |w (DE-627)NLM000152854 |x 1784-973X |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g number:1 |g day:14 |g month:02 |g pages:20-29 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/00015385.2022.2030568 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |e 1 |b 14 |c 02 |h 20-29 | ||